Neuren Pharmaceuticals Limited
Research Neuren Pharmaceuticals Limited (NEU.AX) on Bullrun: market cap AUD 2.56B, P/E 134.7, dividend yield 0.7%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNEU.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 2.56B
- P/E134.7
- Dividend yield0.7%
- Financial periodFY2025
- RevenueAUD 64.63M
- Revenue growth-69.7%
- Net incomeAUD 30.44M
- Free cash flowAUD 125.39M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 2.56B; P/E is 134.7; dividend yield is 0.7%.
Peer valuation comparison
Latest P/E is 134.73x versus a Healthcare sector median of 21.74x (519.6% above).
Latest dividend yield is 0.74% versus a Healthcare sector median of 2.4% (69.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 64.63M | AUD 30.44M | AUD 125.39M | 100.0% | 0.23 | AUD 4.23M | n/a | AUD 338.45M |
| FY2024 | AUD 213.24M | AUD 142.04M | -AUD 11.28M | 100.0% | 1.09 | AUD 3.15M | n/a | AUD 363.90M |
| FY2023 | AUD 231.93M | AUD 157.08M | AUD 184.89M | 100.0% | 1.2 | AUD 17.09M | n/a | AUD 205.21M |
| FY2022 | AUD 14.55M | AUD 184.00K | AUD 3.58M | 100.0% | 0 | AUD 40.18M | n/a | AUD 41.59M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 2.56B | 134.7 | 1.5% | 0.3 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.3 AUD, yield 0.7%.
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neuren Pharmaceuticals Limited's market cap?
Neuren Pharmaceuticals Limited's market capitalization is AUD 2.56B.
What is Neuren Pharmaceuticals Limited's P/E ratio?
Neuren Pharmaceuticals Limited's price-to-earnings (P/E) ratio is 134.7.
Does Neuren Pharmaceuticals Limited pay a dividend?
Neuren Pharmaceuticals Limited has a dividend yield of 0.7%.
What does Neuren Pharmaceuticals Limited do?
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins.